JP2020507596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507596A5 JP2020507596A5 JP2019543851A JP2019543851A JP2020507596A5 JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5 JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- subject
- pharmaceutical composition
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 83
- 239000000427 antigen Substances 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 52
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 42
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 40
- 206010005003 Bladder cancer Diseases 0.000 claims description 39
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 37
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 20
- 229950009791 durvalumab Drugs 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 229910052697 platinum Inorganic materials 0.000 claims description 10
- 229950007217 tremelimumab Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 9
- 238000011275 oncology therapy Methods 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 210000000626 ureter Anatomy 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 210000000244 kidney pelvis Anatomy 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 2
- 210000003803 urachus Anatomy 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 11
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216425A JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Division JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507596A JP2020507596A (ja) | 2020-03-12 |
| JP2020507596A5 true JP2020507596A5 (cg-RX-API-DMAC7.html) | 2021-04-01 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3582805A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020507596A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20190117014A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118001389A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018221822A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3052652A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201991870A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL302777A (cg-RX-API-DMAC7.html) |
| MA (1) | MA47509A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201907211TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018152415A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456756B (zh) * | 2014-05-13 | 2021-04-23 | 免疫医疗有限公司 | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 |
| CN118001389A (zh) * | 2017-02-16 | 2024-05-10 | 免疫医疗有限责任公司 | 膀胱癌的抗pd-l1抗体治疗 |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| WO2021234150A1 (en) * | 2020-05-21 | 2021-11-25 | Astrazeneca Ab | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| CN106456756B (zh) * | 2014-05-13 | 2021-04-23 | 免疫医疗有限公司 | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 |
| BR112017018234A2 (pt) * | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| EP3303632B2 (en) * | 2015-05-29 | 2023-05-10 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| BR112018071287A2 (pt) * | 2016-04-25 | 2019-02-19 | Medimmune, Llc | composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4 |
| CN118001389A (zh) * | 2017-02-16 | 2024-05-10 | 免疫医疗有限责任公司 | 膀胱癌的抗pd-l1抗体治疗 |
-
2018
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| JP2018522850A5 (cg-RX-API-DMAC7.html) | ||
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2013520442A5 (cg-RX-API-DMAC7.html) | ||
| JP2020507596A5 (cg-RX-API-DMAC7.html) | ||
| CN108498532A (zh) | 骨髓抑制的治疗 | |
| Hyung et al. | Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin | |
| JP2018508593A5 (cg-RX-API-DMAC7.html) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2024038034A5 (cg-RX-API-DMAC7.html) | ||
| Lignon et al. | Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| Rose et al. | A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study | |
| Smith et al. | Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody | |
| Fujimoto et al. | A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol | |
| Sun et al. | Programmed cell death 1 (PD‐1)/PD‐ligand 1 (PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| Nardi et al. | FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study | |
| Takeda et al. | Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma | |
| TW202031291A (zh) | 治療對pd-1/pd-l1傳訊抑制劑無反應的癌症之方法及藥物 | |
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| Kojima et al. | Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients |